BioSenic appoints Dr Carole Nicco as Chief Operating Officer in addition to Chief Scientific Officer

PRESS RELEASE

Dr Nicco's new Chief Operating Officer (COO) position will give her a broader mandate at BioSenic, where she is currently responsible for R&D programs.

Mont-Saint-Guibert, Belgium, January 10, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in addition to her position as Chief Scientific Officer (CSO).

Dr Carole Nicco will be involved in the strategic planning, decision-making and management of key initiatives, as well as overseeing and enhancing the strategic development of BioSenic's pipelines, targeting treatments with its viscosupplementation, cell therapy and arsenic trioxide platforms. She will work closely with BioSenic's CEO, Prof. François Rieger, to further oversee and enhance BioSenic's strategic decisions.

“BioSenic is very proud to incorporate Dr Carole Nicco - our CSO - deeper into the strategic planning of BioSenic’s development. We have known Dr Nicco for many years and shared fruitful collaboration with her previous academic setting in Paris. Her enthusiasm and dedication to work, together with her wide experience and successes in the continuously growing field of Immunology, and pioneering results in innate and trained immunology, have deep consequences in creating, with the most advanced techniques in molecular and cell biology, the paths to a new area of modern and personalized medicine, applied to pathologies with no actual decisive medical treatments. We welcome her deep involvement and integration into our global project, with an interesting, diversified approach to efficient medications, using both our main platforms, i.e. the arsenic trioxide platform- to treat autoimmune conditions and return to homeostasis - and the cell therapy platform- to encourage tissue repair mechanisms,” said Prof. François Rieger, President and CEO of BioSenic.

"After one year as BioSenic's CSO, I have a better vision of the company's potential” declares Dr Carole Nicco, PhD and supervisor of graduate students for many years at the University Paris Cité. "I knew the scientific and clinical value of BioSenic's technologies and the importance of the arsenic trioxide platform in developing treatments for autoimmune diseases. The very active and interactive last year, 2023, allowed me to meet key players in the health sciences arena, and I particularly appreciate our growing partnership with the Walloon region, combined with the incredibly fruitful biopharma scene in Belgium. I am delighted to take on strategic responsibilities as Chief Operating Officer by BioSenic's Board and get the opportunity to share the strategic objectives of the Deputy CEO, Véronique Pomi, and the CEO, François Rieger, who have placed a great deal of trust in me. I am thrilled to bring my expertise to facilitate efficiency and effective performance, adding my perspectives and ideas to the overall project of the Company. I already have specific plans for the near, medium, and distant future to improve and diversify the use of our main therapeutic platforms, particularly using arsenic trioxide and its various possible formulations, which I'm convinced will address important unmet medical needs for patients heavily affected by certain autoimmune diseases.”